tert-butyl (4-chlorothiophen-3-yl)carbamate | 937637-29-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: tert-butyl (4-chlorothiophen-3-yl)carbamate
• 英文别名: tert-butyl N-(4-chlorothiophen-3-yl)carbamate
• CAS: 937637-29-1
• 化学式: C₉H₁₂ClNO₂S
• 分子量: 233.719
• InChiKey: QUNUOAYKWNJQFV-UHFFFAOYSA-N

物化性质

• 沸点：
  262.8±25.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-chlorothiophen-3-yl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-chlorothiophen-3-amine hydrochloride
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY
  [FR] INHIBITEURS DE L'ACTIVITÉ D'IRAK4 À BASE DE PYRAZOLOPYRIMIDINE

  摘要：

  本发明涉及式(I)的IRAK4的吡唑吡咯啉抑制剂，并提供包含这种抑制剂的组合物，以及用于治疗IRAK4介导或相关疾病或病症的方法。

  公开号：

  WO2016144846A1
• 作为产物：
  描述：

  4-chlorothiophene-3-carboxylic acid 、 叔丁醇 在 叠氮磷酸二苯酯 、 N,N-二异丙基乙胺 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 tert-butyl (4-chlorothiophen-3-yl)carbamate
  参考文献：
  名称：

  [EN] THIENOPYRAZINE INHIBITORS OF IRAK4 ACTIVITY
  [FR] THÉNOPYRAZINES UTILISÉES COMME INHIBITEURS DE L'ACTIVITÉ DE L'IRAK4

  摘要：

  本发明涉及式(I)的噻吩并吡嗪作为IRAK4的抑制剂，并提供包含此类抑制剂的组合物，以及用于治疗IRAK4介导的或相关的条件或疾病的方法。

  公开号：

  WO2016144849A1

文献信息

• HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF
  申请人：iOmx Therapeutics AG

  公开号：EP3901151A1

  公开（公告）日：2021-10-27

  The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

  该发明涉及激酶抑制剂，特别是蛋白激酶的抑制剂，包括SIK家族CSF1R，ABL/BCR-ABL，SRC，HCK，PDGFR，KIT和/或它们的突变体。尽管在结构上类似于达沙替尼，但该发明的激酶抑制剂具有独特之处；具有一类特殊的卤代杂环芳基。这种激酶抑制剂可能表现出与达沙替尼和其他在结构上相似的激酶抑制剂不同的某些性质。该发明的激酶抑制剂或包含它们的药物组合物可用于治疗某种疾病或病况，例如增生性疾病，例如白血病或实体肿瘤。特别是，这些和其他在结构上相似的激酶抑制剂可用于治疗增生性疾病 - 例如混合表型急性白血病（MPAL）- 其特征包括MEF2C蛋白的存在，11q23处的人类染色体易位，和/或KMT2A融合致癌蛋白。本文披露的激酶抑制剂或药物组合物可用于局部调节受试者的皮肤色素沉着，例如赋予UV保护并降低皮肤癌风险。
• [EN] PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY<br/>[FR] INHIBITEURS DE PYRROLOTRIAZINE DE L'ACTIVITÉ D'IRAK4
  申请人：MERCK SHARP & DOHME

  公开号：WO2016144848A1

  公开（公告）日：2016-09-15

  The present invention relates to pyrrolotriazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

  本发明涉及式(I)的IRAK4的吡咯三嗪抑制剂，并提供包含这些抑制剂的组合物，以及用于治疗IRAK4介导的或相关的疾病或病症的方法。
• [EN] PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY<br/>[FR] INHIBITEURS À BASE DE PYRROLOPYRIDAZINE D'ACTIVITÉ D'IRAK4
  申请人：MERCK SHARP & DOHME

  公开号：WO2016144847A1

  公开（公告）日：2016-09-15

  The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

  本发明涉及式(I)的IRAK4的吡咯吡啶嘧啶抑制剂，并提供包含这种抑制剂的组合物，以及用于治疗IRAK4介导的或相关的疾病或症状的方法。
• Novel thienopyrrole glycogen phosphorylase inhibitors: Synthesis, in vitro SAR and crystallographic studies
  作者：Paul R.O. Whittamore、Matthew S. Addie、Stuart N.L. Bennett、Alan M. Birch、Michael Butters、Linda Godfrey、Peter W. Kenny、Andrew D. Morley、Paul M. Murray、Nikos G. Oikonomakos、Ludovic R. Otterbein、Andrew D. Pannifer、Jeremy S. Parker、Kristy Readman、Pawel S. Siedlecki、Paul Schofield、Andy Stocker、Melvyn J. Taylor、Linda A. Townsend、David P. Whalley、Jennifer Whitehouse

  DOI：10.1016/j.bmcl.2006.08.047

  日期：2006.11

  Two series of novel thienopyrrole inhibitors of recombinant human liver glycogen phosphorylase a (GPa) which are effective in reducing glucose output from rat hepatocytes are described. Representative compounds have been shown to bind at the dimer interface site of the rabbit muscle enzyme by X-ray crystallography.
• [EN] HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE HÉTÉROARYLES HALOGÉNÉS ET AUTRES HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：IOMX THERAPEUTICS AG

  公开号：WO2021214117A1

  公开（公告）日：2021-10-28

  The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.